{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:59:46Z","timestamp":1787839186938,"version":"build-2784847793"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012499","name":"Chicago Center for Diabetes Translation Research","doi-asserted-by":"publisher","award":["P30DK092986"],"award-info":[{"award-number":["P30DK092986"]}],"id":[{"id":"10.13039\/100012499","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007217","name":"Health Services Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015728","name":"Clinical Science Research and Development","doi-asserted-by":"publisher","award":["CX000570-12"],"award-info":[{"award-number":["CX000570-12"]}],"id":[{"id":"10.13039\/100015728","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Medicine Open"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ajmo.2025.100105","type":"journal-article","created":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T10:16:22Z","timestamp":1748168182000},"page":"100105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The Association of SGLT2i vs DPP4i on Fracture: A Cohort Study in Veterans with Diabetes"],"prefix":"10.1016","volume":"14","author":[{"given":"Kathryn","family":"Snyder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7755-3732","authenticated-orcid":false,"given":"Katherine","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0164-6589","authenticated-orcid":false,"given":"Amber","family":"Hackstadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Javid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Greevy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6555-2055","authenticated-orcid":false,"given":"Christianne L.","family":"Roumie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ajmo.2025.100105_bib0001","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.pop.2021.11.004","article-title":"Diabetes-associated comorbidities","volume":"49","author":"Teck","year":"2022","journal-title":"Prim Care"},{"issue":"4","key":"10.1016\/j.ajmo.2025.100105_bib0002","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2337\/dc06-1851","article-title":"The risk of hip fractures in older individuals with diabetes: a population-based study","volume":"30","author":"Lipscombe","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ajmo.2025.100105_bib0003","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2147\/TCRM.S131945","article-title":"Fracture risk in patients with type 2 diabetes mellitus and possible risk factors: a systematic review and meta-analysis","volume":"13","author":"Moayeri","year":"2017","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"10.1016\/j.ajmo.2025.100105_bib0004","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12902-018-0290-y","article-title":"Effect of duration of diabetes on bone mineral density: a population study on East Asian males","volume":"18","author":"Jang","year":"2018","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.ajmo.2025.100105_bib0005","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2147\/CIA.S150067","article-title":"Quality of life and psychological consequences in elderly patients after a hip fracture: a review","volume":"13","author":"Alexiou","year":"2018","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.ajmo.2025.100105_bib0006","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.2147\/DDDT.S69926","article-title":"Empagliflozin in the treatment of type 2 diabetes: evidence to date","volume":"9","author":"Shubrook","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"10.1016\/j.ajmo.2025.100105_bib0007","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S2213-8587(14)70227-X","article-title":"SGLT2-inhibitors trigger downstream mechanisms that may exert adverse effects upon bone","volume":"3","author":"Taylor","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ajmo.2025.100105_bib0008","article-title":"Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes \u2013 data from a randomized, placebo-controlled study","volume":"16","author":"Rau","year":"2022","journal-title":"Bone Rep"},{"issue":"1","key":"10.1016\/j.ajmo.2025.100105_bib0009","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1210\/jc.2015-1860","article-title":"Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin","volume":"101","author":"Bilezikian","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ajmo.2025.100105_bib0010","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2337\/dc14-1237","article-title":"Efficacy and safety of canagliflozin, an inhibitor of sodium\u2013glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes","volume":"38","author":"Neal","year":"2015","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.ajmo.2025.100105_bib0011","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ajmo.2025.100105_bib0012","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ajmo.2025.100105_bib0013","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ajmo.2025.100105_bib0014","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","article-title":"Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction","volume":"143","author":"Packer","year":"2021","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.ajmo.2025.100105_bib0015","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajmo.2025.100105_bib0016","volume":"13","author":"Chai","year":"2022","journal-title":"Front Pharmacol"},{"issue":"Supplement_1","key":"10.1016\/j.ajmo.2025.100105_bib0017","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.2337\/dc24-S004","article-title":"4. Comprehensive medical evaluation and assessment of comorbidities: Standards of care in diabetes\u20142024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.ajmo.2025.100105_bib0018","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00198-019-04968-x","article-title":"Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies","volume":"30","author":"Hidayat","year":"2019","journal-title":"Osteoporos Int"},{"issue":"24","key":"10.1016\/j.ajmo.2025.100105_bib0019","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ajmo.2025.100105_bib0020","article-title":"Target trial emulation: applying principles of randomised trials to observational studies","volume":"378","author":"Matthews","year":"2022","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.ajmo.2025.100105_bib0021","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/pds.5662","article-title":"Validation of an algorithm to identify fractures among patients within the Veterans Health Administration","volume":"32","author":"Horton","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ajmo.2025.100105_sbref0022","series-title":"Recommendations for implementing the CKD-EPI 2021 race-free eGFR calculation: guidelines for clinical laboratories","year":"2021"},{"issue":"2","key":"10.1016\/j.ajmo.2025.100105_bib0024","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1515\/ijb-2012-0030","article-title":"A weighting analogue to pair matching in propensity score analysis","volume":"9","author":"Li","year":"2013","journal-title":"Int J Biostat"},{"issue":"451","key":"10.1016\/j.ajmo.2025.100105_bib0025","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1080\/01621459.2000.10474263","article-title":"Estimating and using propensity scores with partially missing data","volume":"95","author":"D\u2019Agostino","year":"2000","journal-title":"J Am Stat Assoc"},{"issue":"12","key":"10.1016\/j.ajmo.2025.100105_bib0026","first-page":"1946","article-title":"Comparing the performance of propensity score methods in healthcare database studies with rare outcomes","volume":"36","author":"Franklin","year":"2017","journal-title":"Stat Med"},{"key":"10.1016\/j.ajmo.2025.100105_bib0027","series-title":"Flexible Imputation of Missing Data","author":"Van Buuren","year":"2012"},{"issue":"3","key":"10.1016\/j.ajmo.2025.100105_bib0028","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"key":"10.1016\/j.ajmo.2025.100105_bib0029","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1471-2288-9-57","article-title":"Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines","volume":"9","author":"Marshall","year":"2009","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"10.1016\/j.ajmo.2025.100105_bib0030","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/pan\/mpl013","article-title":"Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference","volume":"15","author":"Ho","year":"2007","journal-title":"Polit Anal"},{"issue":"2-3","key":"10.1016\/j.ajmo.2025.100105_bib0031","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/0049124189018002003","article-title":"An introduction to bootstrap methods: examples and ideas","volume":"18","author":"STINE","year":"1989","journal-title":"Sociol Methods Res"},{"key":"10.1016\/j.ajmo.2025.100105_bib0032","unstructured":"R: the R project for statistical computing. Accessed July 8, 2022. https:\/\/www.r-project.org\/."},{"key":"10.1016\/j.ajmo.2025.100105_bib0033","unstructured":"Research C for DE. FDA Drug Safety Communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density. FDA. 2019. Accessed April 12, 2024. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-revises-label-diabetes-drug-canagliflozin-invokana-invokamet."},{"issue":"4","key":"10.1016\/j.ajmo.2025.100105_bib0034","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.ajmo.2025.100105_bib0035","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1210\/jc.2015-3167","article-title":"Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus","volume":"101","author":"Watts","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ajmo.2025.100105_bib0036","doi-asserted-by":"crossref","first-page":"e2903","DOI":"10.1002\/dmrr.2903","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis","volume":"33","author":"Ruanpeng","year":"2017","journal-title":"Diabetes Metab Res Rev"},{"issue":"12","key":"10.1016\/j.ajmo.2025.100105_bib0037","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/dom.12742","article-title":"Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials","volume":"18","author":"Tang","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.ajmo.2025.100105_bib0038","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.2337\/dc17-1525","article-title":"Analysis of fractures in patients with type 2 diabetes treated with empagliflozin in pooled data from placebo-controlled trials and a head-to-head study versus glimepiride","volume":"41","author":"Kohler","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ajmo.2025.100105_bib0039","author":"Zinman"},{"issue":"21","key":"10.1016\/j.ajmo.2025.100105_bib0040","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ajmo.2025.100105_bib0041","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2337\/dc19-1476","article-title":"Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE\u2013TIMI 58 study","volume":"43","author":"Cahn","year":"2019","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.ajmo.2025.100105_bib0042","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1111\/dom.14474","article-title":"Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: an observational study using data from routine care","volume":"23","author":"Fralick","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.ajmo.2025.100105_bib0043","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/dom.13176","article-title":"Initiation of dapagliflozin and treatment-emergent fractures","volume":"20","author":"Toulis","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ajmo.2025.100105_bib0044","article-title":"SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: a nationwide cohort study","volume":"13","author":"Al-Mashhadi","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.ajmo.2025.100105_bib0045","doi-asserted-by":"crossref","first-page":"k4365","DOI":"10.1136\/bmj.k4365","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study","volume":"363","author":"Ueda","year":"2018","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.ajmo.2025.100105_bib0046","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/pds.4900","article-title":"Sodium-glucose co-transporter 2 inhibitors and the risk of fractures: a propensity score-matched cohort study","volume":"28","author":"Adimadhyam","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.ajmo.2025.100105_bib0047","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2215\/CJN.16171221","article-title":"Fracture risk of sodium-glucose cotransporter-2 inhibitors in chronic kidney disease","volume":"17","author":"Cowan","year":"2022","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"suppl_1","key":"10.1016\/j.ajmo.2025.100105_bib0048","first-page":"S140","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142023","volume":"46","author":"ElSayed","year":"2022","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.ajmo.2025.100105_bib0050","doi-asserted-by":"crossref","first-page":"745","DOI":"10.14740\/jocmr3112w","article-title":"Effect of sodium glucose cotransporter 2 inhibitors with low SGLT2\/SGLT1 selectivity on circulating glucagon-like peptide 1 levels in type 2 diabetes mellitus","volume":"9","author":"Takebayashi","year":"2017","journal-title":"J Clin Med Res"}],"container-title":["American Journal of Medicine Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667036425000196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667036425000196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T04:20:45Z","timestamp":1765254045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667036425000196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":48,"alternative-id":["S2667036425000196"],"URL":"https:\/\/doi.org\/10.1016\/j.ajmo.2025.100105","relation":{},"ISSN":["2667-0364"],"issn-type":[{"value":"2667-0364","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Association of SGLT2i vs DPP4i on Fracture: A Cohort Study in Veterans with Diabetes","name":"articletitle","label":"Article Title"},{"value":"American Journal of Medicine Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajmo.2025.100105","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100105"}}